Brain scans and genetics to guide early schizophrenia treatment
Treatments studied
Part of Mental health clinical trials.
This study tests whether using brain scans and genetic tests can help choose the best treatment for people early in their schizophrenia. It will check if these biomarkers can predict who will respond better to medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 35 years old.
- You have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder within the last few years.
- You have taken antipsychotic medication for a total of 4 weeks or less in your life.
- You do not have certain high-risk genetic markers or brain connectivity issues that might affect treatment.
- You are willing to have an MRI scan and genetic testing.
- You are not currently using substances (except nicotine, alcohol, or cannabis in mild amounts) and are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether using a genetic test (pharmacogenomics) can help doctors choose the right antipsychotic medication for people with schizophrenia whose current treatment is not working well or causes side effects. The goal is to find a better medicine match for you.
This study uses brain scans to find markers that can predict how well antipsychotic medications work in people having their first episode of psychosis. It aims to help doctors choose the right treatment earlier.
This study looks for a biological signature in the brain and blood to help doctors tell apart different types of psychosis early on. It may help people with schizophrenia, bipolar disorder, or major depression understand their condition better.
This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.
This study looks at how psychosis symptoms and development change over time in children and teens. It may help doctors better understand different patterns of illness and how to support young people with these disorders.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
Hear when a new Schizophenia Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.